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Purpose: To determine the temporal lobe (TL) damage rate in 96 patients treated with high-dose proton and
photon irradiation for chordomas and chondrosarcomas of the base of the skull.
Methods and Materials: The records of 96 consecutive patients treated at Massachusetts General Hospital
(MGH) and Harvard Cyclotron Laboratory (HCL) between June 1984 and 1993, for chordomas and chondro-
sarcomas of the base of the skull were reviewed. All the patients had undergone some degree of resection of the
tumor prior to radiation therapy. Seventy-five patients were classified as “primary tumors” and 21 as recurrent
or regrowing tumors after one or more surgical procedures. All the patients were randomized to receive 66.6 or
72 cobalt Gray equivalent (CGE) on a prospective dose-searching study by proton and photon irradiation
(Radiation Therapy Oncology Group #85-26) with conventional fractionation (1.8 CGE/day, 5 fractions/week).
All treatments were planned using the three-dimensional (3D) planning system developed at the Massachusetts
General Hospital, and the dose was delivered using opposed lateral fields for the photon component and a
noncoplanar isocentric technique for the proton component. Clinical symptoms of TL damage were classified into
4 grades. Computerized tomography (CT) and magnetic resonance imaging (MRI) scans were evaluated for
white matter changes. Abnormalities associated with persistent or recurrent tumor were distinguished from
radiation-induced changes. TLs were delineated on the original scans of the 10 patients with damage and those
of a group of 33 patients with no clinical or MRI evidence of injury. Dose distributions were calculated and
dose–volume histograms were obtained for these patients.
Results: Of the patients, 10 developed TL damage, with bilateral injury in 2 and unilateral injury in 8. The
cumulative TL damage incidence at 2 and 5 years was 7.6 and 13.2%, respectively. The MRI areas suggestive of
TL damage were always separated from the tumor bed. Symptoms were severe to moderate in 8 patients. Several
baseline factors, tumor- or host-related, were analyzed to evaluate their predictivity for TL damage: age, gender,
tumor site, histology, type of presentation, type and number of surgical procedures, primary tumor volume,
prescribed dose, normal tissue involvement, and volume of TL receiving doses ranging between 10 and 50 CGE
or more. Only gender, in a univariate analysis (log rank) was a significant predictor of damage (0.0155), with
male patients being at significantly higher risk of TL injury. In a stepwise Cox regression that included gender
as a variable, no other baseline variable improved the prediction of damage.
Conclusions: The 2- and 5-year cumulative TL damage rates were 7.6 and 13.2%, respectively. Despite the
different TL damage rates related to age, tumor volume, number of surgical procedures prior to radiation
therapy, and prescribed doses to the tumor, only gender was a significant predictor of damage (p 5 0.0155) using
a univariate (log rank) test. Chordomas and chondrosarcomas of the base of the skull may represent an
interesting model to evaluate the TL damage rates because of their extradural origin, displacing the white matter
instead of infiltrating it as gliomas do, because of their longer local recurrence-free survival other than gliomas
and other brain tumors and because of the high doses of irradiation delivered to the target volume to obtain local
control. © 1998 Elsevier Science Inc.
High-dose fractionated radiation, Skull base tumors, Central-nervous-system tolerance, Late radiation effects,
Proton therapy, 3D treatment planning.
INTRODUCTION
The physical properties of the proton beam that make it
attractive for radiation therapy are represented by their finite
range in tissues due to the Bragg peak and sharply defined
lateral beam edges. These features provide the basis for
proton dose distributions that are superior to those obtain-
able with photons in many tumor to healthy tissue relation-
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ships, particularly at the base of the skull. The dose deliv-
ered to a tumor using protons can, consequently, be
increased to a certain extent, with proton beam therapy
(PBT), relative to that which can be delivered with photon
therapy while maintaining a comparable rate of treatment-
related morbidity. This difference in volume of healthy
tissues included in comparison to photons is primarily due
to minimal dose beyond the target due to the Bragg peak of
the proton radiation.
Chordomas and chondrosarcomas of the base of the skull
present a worthy challenge to the neurosurgeon and the
radiation oncologist and are judged to be a good example of
tumors that may likely benefit from high-dose proton radi-
ation. With photon radiation therapy, only moderate doses
of radiation can be delivered to the primary target, and most
of these patients die with locally progressive disease (1).
The total dose that can safely be delivered to the tumor is
limited by the close proximity of healthy structures, such as
the brain stem, temporal lobes, and optic chiasm and nerves.
As a consequence of these particular tumor-healthy tissue
relationships, and of the vital importance of the nervous
structures, clinicians limit the radiation dose to levels tol-
erated by these structures (although the dose–response re-
lationship for the central nervous system (CNS) has not yet
been completely assessed) (2). Irradiation of the CNS can,
in fact, produce a wide range of clinically expressed, as well
as silent, injuries in the brain (3–5), which have been
described in patients receiving doses in excess of 45 Gy (6).
Identification of radiation damage as a distinct entity
from the effects of the tumor growth, surgical procedures, or
other incidental pathologies is crucial to devise new proto-
cols for dose-escalation studies, and to evaluate retrospec-
tively the cost-benefit of the clinical achievements. The
knowledge of the tolerance dose of the healthy tissues is
essential to maximize the dose prescribed to the targets and,
thereby, achieve the highest tumor control with a low prob-
ability of damaging healthy surrounding tissues.
To contribute to the comprehension of CNS late effects,
after high-dose irradiation, we report our experience based
on an analysis of 96 consecutive patients affected by chor-
domas or chondrosarcomas of the base of the skull who
were treated with high-dose proton and photon irradiation
and were randomized to receive 66.6 or 72 CGE on a
controlled, prospective dose-searching study. The aim of the
present study was to examine the correlation between clin-
ical and imaging signs of temporal lobe damage and dose,
features of the tumor, distortion of the normal anatomy
induced by the tumor, number of surgical procedures, and
other host characteristics.
METHODS AND MATERIALS
Ninety-six consecutive patients with chordomas and
chondrosarcomas of the base of the skull were randomized
to receive 66.6 or 72 CGE in a prospective dose-searching
study (RTOG-Radiation Therapy Oncology Group #85-26)
by proton and photon techniques at the Massachusetts Gen-
eral Hospital (MGH) and Harvard Cyclotron Laboratory
(HCL) between July 1984 and July 1993.
The patients ranged in age from 11 to 80 years, with a
median of 44 years; there were 51 males and 45 females. Of
the tumors, 41 were classified as arising from the occipital
bone (OB), 26 from the sphenoid bone (SB), 28 from the
temporal bone (TB), and one mainly involving the naso-
pharynx (NA). The histology of the tumors were 49 chor-
domas (17 of 49 chondroid chordomas (CC) and 32 of 49
nonchondroid chordomas NCC)) and 47 chondrosarcomas
(28 of 47 intermediate-grade chondrosarcomas (IGCS) and
19 of 47 low-grade chondrosarcomas (LGCS)). All histo-
logical diagnoses were confirmed by the Sarcoma Section of
the Massachusetts General Hospital Pathology Department.
All the patients had previously undergone biopsy or sub-
total removal of the tumor. The type of surgical approaches
have been classified as craniotomy-type or noncraniotomy-
type, including in the latter category the transsphenoidal,
transoral, transpalatine, or lateral rhinotomy techniques.
Of the patients, 75 were treated for a primary tumor,
having been referred for radiation therapy immediately after
one or more debulking surgeries; 21 underwent treatment
for persistent and/or recurrent tumors with a median and
mean time, between surgery and irradiation, of 26 and 44
months, respectively.
Only one surgical procedure was performed in 64 pa-
tients; 32 patients underwent more than one surgery and
more than 50% of these (18 of 32) were performed in the
group of 21 patients with persistent and/or recurrent tumors
(Table 1).
The treatments were delivered as 1.8 CGE/fraction with 5
fractions a week. The proton dose is reported in CGE, which
is the physical dose times the relative biological effective-
ness of protons, relative to 60cobalt, of 1.10 (7). Many
experimental determinations of RBE have been made, using
cell cultures and in animals, and have yielded a range
(0.78–1.32) of RBEs for protons (7, 8). The value of 1.10
was selected from early experiments, has been used since
the beginning of the clinical treatments at HCL-MGH, and
seems to be consistent with the clinical response of patients.
The Harvard Cyclotron is available only 4 times a week
and the total dose was delivered with 4 proton fractions a
week and one photon fraction (10 MeV X-rays from a linear
accelerator). The delivered total dose to the primary target
volume ranged between 64.8 and 72 CGE (median dose
68.4). The proton contribution to the total dose ranged
between 30.6 and 66.2 CGE. One patient only received a
low proton dose (30.6 CGE) and the median and average
proton doses were 55.8 and 55.3, respectively. The photon
contribution to the overall dose to the target volume ranged
between 5.4 and 36 Gy, with one patient only receiving 36
Gy with X-rays (median and average photon doses being
12.6 and 13.9, respectively).
The treatment philosophy was to deliver the prescribed
dose to as much as possible of the tumor while maintaining
the brain stem, the spinal cord, and optic structures at or
below dose constraints; the dose constraints of the healthy
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tissues, surrounding the tumors, were lower than the pre-
scribed doses to the target volume. A lower than prescribed
dose was, consequently, delivered to small portions of the
tumor encroaching into the brain stem or abutting the optic
chiasm or optic nerves so that the doses to these structures
would not exceed the following values: #64 CGE, #53
CGE, #48 CGE to the surface of the spinal cord or brain-
stem, to the center of the spinal cord or brain stem, and to
the point on the spinal cord or brain-stem surface opposite
the point receiving the highest doses, and #60 CGE to the
optic chiasm and both optic nerves. In cases where tumor
abutted one optic nerve, and vision in the contralateral eye
was good, that optic nerve could get #64 CGE.
Overall treatment time ranged between 50 and 71 days
(median and mean values 55 and 55.3 days, respectively),
with a total number of fractions ranging between 37 and 40.
Primary volumes ranged between 5 and 135 cc with a
median and average volume of 40 and 43.2 cc, respectively.
Patient characteristics are summarized in Table 1.
All the treatments were planned using the 3D treatment-
planning system developed at Massachusetts General Hos-
pital (MGH) (9, 10). With the patient immobilized in the
treatment position, 3-mm thick contiguous CT scan sections
were obtained. All the volumes of interest (primary and
secondary targets, brain stem, optic chiasm and nerves, and
temporal lobes) were delineated on the CT scans using all
the available information (radiographic, MRI, and CT stud-
ies, clinical data, and operative findings). Multiple treatment
fields were designed for each patient, individualizing the
treatment technique so as to minimize dose to the normal
structures and deliver the prescribed dose to as much as
possible of the primary target volume. Brass apertures were
used to shape the edges of the fields and lucite compensators
were used to shape the distal edge of the beam, to ensure
adequate tumor coverage (11, 12). Before treatment, patient
position relative to the beam center and aperture edges was
verified radiographically by comparing diagnostic X-ray
portal film and a digital reconstructed radiograph derived
from the CT data. Day-to-day reproducibility was within 6
2 mm (13).
Patient follow-up has continued from 18 to 126 months,
with a median and mean follow-up time of 41 and 43.8
months, respectively. Follow-up examinations included a
general physical and neurological examination every 6
months after treatment for the first 3 to 5 years, and then
annually thereafter. CT and MRI scans of the brain and
chest X-rays were generally obtained annually, or more
frequently when clinically indicated.
To evaluate temporal lobe damage rate, all the available
images and clinical documents of these patients have been
reviewed.
The clinical symptoms, related to white matter changes in
the temporal lobe as shown by the CT and MRI images,
were classified into 4 grades according to the criteria re-
ported in Table 2. Such a scoring system is a modification
of the RTOG/EORTC Late Morbidity Scoring Scheme. CT
and MRI abnormalities associated with persistent or recur-
rent tumor or changes induced in the normal tissues by
surgery could be distinguished from white matter modifica-
Table 2. Neurologic toxicity criteria
Mental status Seizures Motor function
Gr. 1: Mild subjective
memory loss or
transient alteration
of mental status
– –
Gr. 2: Moderate
subjective memory
loss or mental
disorder status
alteration
substantially
affecting function
Transient
seizure
Substantially affects
function: ,50%
decrease of
baseline
capabilities
Gr. 3: Severe memory
loss affecting
function ,50% of
time
Seizure disorder
controlled by
medical
therapy
Substantially affects
function: .50%
decrease of
baseline
capabilities
Gr. 4: Coma Seizure disorder
not controlled
by medical
therapy
Paralysis
Modified RTOG-EORTC late morbidity scoring system.
Table 1. Patient characteristics
Characteristic n
Age
#50 64
.50 32
Gender
Male 51
Female 45
T-site
Occipital bone 41
Sphenoid bone 26
Temporal bone 28
Nasopharynx 1
Histology
Chondroid chordoma 17
Nonchondroid chordoma 32
Intermediate-grade chondrosarcoma 28
Low-grade chondrosarcoma 19
Type of presentation
Primary tumor 75
Persistent and or recurrent tumor 21
Number of surgical procedures
1 Surgery 64
.1 Surgery 32
Type of surgical procedure
Craniotomy 58
Noncraniotomy 38
Primary target volume
,70 cc 83
$70 cc 13
Prescribed dose (CGE) to the target volume
66.6 44
72 52
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tions induced by the treatment that appeared during fol-
low-up as areas separated from the site of the tumor bed.
Temporal lobes were outlined on the planning CT scans
for all the patients with damage and for 33 patients selected
among those without clinical and/or radiographic evidence
of TL injury or of white matter changes, after radiation
therapy. The Control Group was selected to match the
patients with damage with respect to follow-up time, site,
volume and histology of the tumor, and dose delivered to
the target. A neuroanatomist (B. F.) determined volume
using brain and skull landmarks visible on the CT and MRI
scans. Using the MGH 3D treatment-planning system, the
total volume of the temporal lobes were calculated, dose-
volume histograms have been obtained, and the dose distri-
butions have been recalculated.
The Kaplan–Meier product-limit method was used to
estimate probability of freedom from temporal lobe dam-
age, with statistical inferences on actuarial curves made by
using the log rank test. The Cox proportional-hazards re-
gression model was used to assess the simultaneous effect
of several baseline parameters on the risk of temporal lobe
damage. All baseline variables were dichotomized for this
analysis.
RESULTS
The 2- and 5-year cumulative TL damage rates were 7.6
and 13.2%, respectively (standard errors 2.8 and 4.1, re-
spectively). Ten patients with TL damage were identified, 1
with MRI white matter changes only, and 9 with both MRI
changes and clinically evident TL injury. One had Grade 2
and 8 had Grade 3 injury. One patient developed multiple
Grade 2 symptoms and 7 suffered Grade 3 symptoms (4 of
7 one Grade 3 only, 2 of 7 multiple Grade 3, and 1 of 7
Grade 3 and 2). Epilepsy and deterioration of the mental
status with impairment of short- or long-term memory were
associated in 3 patients. The clinical features of the 10
patients with TL damage are repeated in Table 3. Severity of
the clinical symptoms in 9 of 10 patients with TL damage is
reported in Table 4.
Two patients showed bilateral TL damage and, in 8, 1
temporal lobe showed postirradiation changes. Five patients
with unilateral damage presented with tumor located in the
center of the base of the skull and, in 3, the disease had
grown to the temporal lobe. In 3 patients, the damage was
ipsilateral to tumor side. The 2 patients with bilateral TL
damage presented a centrally located tumor in 1 case and a
prevalently lateral tumor in the other one. Three patients
were reoperated to resect the injured area in the temporal
lobe and, in all of them, radionecrosis was pathologically
documented.
White matter in the temporal lobes was always charac-
terized, on the MRI scans, by a generalized increase in the
signal intensity on T2-weighted images and was located in
the anterior portion of the TL extending medially and pos-
teriorly. Figures 1A, B and 2 show two examples of TL
damage in 2 patients with unilateral (Fig. 1) and bilateral
(Fig. 2) lesions, respectively.
The present status of the 10 patients with TL damage is
reported in Table 5. Seven patients showed improvement
Table 3. Clinical features of 10 patients with TL damage
Patient Gender Age Tumor site
Type of
presentation Histology
Surgery Tumor
volume
(cc)
Prescribed
dose
(CGE)Type n
1 M 51 OB Recurrent CC Transphenoidal 2 135 72
Infratemporal cr. 1 – –
Pterional cr. 1 – –
2 M 61 SB Primary NCC Sublabial 1 30 72
3 M 66 OB Primary NCC Lateral rhinot. 2 81 72
4 M 48 TB Primary IGCS Subtemporal cr. 1 56 72
5 F 52 SB Primary NCC Transphenoidal 1 8 66.6
6 M 40 OB Primary NCC Suboccipital cr. 1 29 66.6
Transnasal 1 – –
7 M 22 SB Recurrent LGCS Pterional cr. 2 46 72
8 M 60 OB Primary NCC Transmaxillary 1 113 66.6
9 M 51 SB Primary LGCS Temporal cr. 1 15 72
10 M 26 TB Recurrent IGCS Temporal cr. 2 72 66.6
OB 5 occipital bone; SB 5 sphenoid bone; TB 5 temporal bone; CC 5 chondroid chordoma; NCC 5 Nonchondroid chordoma; IGCS 5
intermediate-grade chondrosarcoma; LGCS 5 low-grade chondrosarcoma.
Table 4. Clinical symptoms at the diagnosis of TL damage
Patient
Grade (clinical symptoms)
Headache Motor function Seizures Mental status
1 – 2 2 2
2 – – 3 2
3 1 – – –
4 – – 3 –
5 – – 3 3
6 – – 3 3
7 – – – 3
9 – – – 3
10 3 – – –
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after medical or surgical treatment; 1 (Patient 3 of Table 5)
experienced a local recurrence 1 year after the diagnosis of
TL damage and died of locally progressive disease after 30
months. One patient was clinically stable, but recurrent
tumor was diagnosed 9 months after onset of damage to the
right temporal lobe (Patient 8 of Table 5). Two patients
(Number 7 and 9 of Table 5) whose symptoms were not
controlled by the medical treatment experienced progressive
symptoms without evidence of regrowing tumor.
The following clinical and pathologic factors were eval-
uated to determine if they were associated with TL damage
of any grade: age, gender, tumor site, histology, type of
presentation, type and number of surgical procedures, pri-
Fig. 1. MRI changes induced in the TL after high-dose photon and
proton irradiation for base of the skull tumors in a patient with
unilateral TL damage, which is visible as (A) an oval-shaped area
of increased signal separated by the tumor bed. The black arrow-
heads indicate the TL damage area and black arrows the upper
portion of the tumor site. (B) shows the MRI appearance of the
right temporal lobe after surgery to resect the damaged area (black
arrowheads). Pathology of the resected brain tissue demonstrates
the presence of necrosis.
Fig. 2. Bilateral temporal lobe damage represented by two, almost
symmetrical, irregularly shaped areas of increased signal (black
arrowheads) on the inner aspect of both of the temporal lobes.
Table 5. Status of the patients and evolution of the symptoms
after treatment of the TL damage
Patient Clinical symptoms Status*
1 Partial improvement after surgical resection;
persistent loss of memory
A.P.R.
2 Complete recovery after surgical resection A.C.R.
3 Improved after surgical resection; local
recurrence; dead local disease
D.D.
4 Complete control of seizures A.C.R.
5 Deteriorated mental condition A.C.R.
6 Complete control of seizures; persistent
memory impairement
A.P.R.
7 Increasing memory loss A.S.E.
8 Initially asymptomatic; local recurrence;
cerebral infarction
A.D.
9 Increasing memory loss A.S.E.
10 Complete control of seizures A.C.R.
* A.C.R. 5 Alive with complete recovery; A.P.R. 5 alive with
partial recovery; A.S.E. 5 alive with side effects; A.D. 5 alive
with local progressive disease; D.D. 5 dead with local progressive
disease.
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mary volume tumor, prescribed dose, normal tissue involve-
ment by the tumor prior to radiation therapy, and volume of
temporal lobe receiving escalating doses. Table 6 reports the
TL damage rates with respect to the examined clinical and
pathologic parameters. A tendency to a higher rate of tem-
poral lobe damage was indicated for the older patients (5%
vs. 22%, respectively, for the age groups #50 and .50
years old), the male sex (18% vs. 2%, respectively, for
males and females), primary tumor volume greater than 70
cc (7% vs. 31%, respectively, for the tumor volumes ,70
and $70 cc), more than one surgical procedure (8% vs.
16%, respectively, for only one or more than one surgical
procedure), and higher radiation doses (7% vs. 13% for the
66.6 and 72 CGE groups, respectively). In addition to the
temporal lobe damage rate, the significance of each for
predicting damage from a univariate (log rank) test, are
reported. Only gender was a significant predictor of damage
(p 5 0.0155). In a stepwise Cox regression, which included
gender as a variable, no other baseline variable significantly
improved the prediction of TL damage.
No statistically significant difference was found when the
average volumes of temporal lobes receiving increasing
doses in the patients expressing damage, were compared
with the average volumes of temporal lobes receiving those
doses in patients without damage (Table 7).
As an example, we report here the short summaries of the
clinical histories of 2 of the 10 patients with TL damage,
who may be considered representative of the entire group.
Patient A (#1 of Table 5).
Patient 1 is a black 51-year-old man with a history of
headache and diplopia since the age of 15. At the end of
1990, he noticed the onset of facial numbness, ipsilateral
diplopia, and ptosis on the right side. CT and MRI scans
demonstrated a 6 3 6 cm right parasellar tumor with ex-
tension into the sphenoid sinus, sella, right prepontine cis-
terns, and infratemporal and temporal fossa encasing the
right internal carotid artery. Following a sublabial trans-
sphenoidal biopsy that established the diagnosis of chor-
doma, a partial tumor resection via an infratemporal fossa
approach, and a transfacial, transsphenoidal approach in 2
separate procedures for further debulking of the tumor were
accomplished. Fifteen months later, progressive decrease of
vision in the right eye was treated with a fourth surgical
approach via a right pterional craniotomy, to decompress
the right optic nerve. Following that surgery, the vision
recovered completely, but postoperative MRI showed a
large residual right parasellar mass that compressed and
displaced adjacent temporal lobe. The right middle cerebral
artery was encased by the tumor. The patient was treated
from October through December 1992. Two opposed lateral
fields were treated with 10-MeV X-rays, and multiple non-
coplanar, isocentric proton portals were employed, deliver-
ing 72 CGE in 40 fractions to the primary target volume.
In November 1993, the patient developed loss of memory
and energy, dysarthria, ataxia, and dysmetria. An MRI was
obtained showing the presence of an abnormal increased T2
signal in the right anterior temporal lobe. In December
1993, he underwent surgery to remove necrotic brain tissue
from the right middle fossa. Postoperatively, the patient’s
symptoms partially recovered, but with persistent loss of
memory and decreased energy.
Dose–volume histograms of the temporal lobes are
shown in Fig. 3. Review of the dose distribution showed a
Table 7. Volumes of 78 TL receiving escalating doses
Dose (CGE)
Average volume of TL in cc
p value
No TL damage
(66 of 78)
TL damage
(12 of 78)
$10 46.3 51.6 0.429
$20 34.7 43.0 0.142
$30 21.1 29.1 0.051
$40 12.8 16.6 0.385
$50 8.0 11.8 0.330
* Comparison between TL with damage (12 of 10 patients) and
the Control Group (66 outlined TL in 33 control patients).
Table 6. TL damage and clinical- and tumor-related parameters
Variable
Patients with
damage (%) p value
Age
#50 3 of 64 (5%)
.50 7 of 32 (22%) 0.191
Gender
Males 9 of 51 (18%)
Females 1 of 45 (2%) 0.0155
Tumor site
OB 4 of 41 (10%)
SB 4 of 26 (15%) 0.437
TB 2 of 28 (7%)
Histology
CC 1 of 17 (6%)
NCC 5 of 32 (16%)
IGCS 2 of 28 (7%) 0.619
LGCS 2 of 19 (10%)
Type of presentation
Primary t. 7 of 75 (9%)
Recurrent t. 3 of 21 (14%) 0.513
Tumor volume
$70 cc 4 of 13 (31%)
,70 cc 6 of 83 (7%) 0.391
Intracranial arteries involvement*
Absent 4 of 43 (9%)
1 artery 2 of 35 (11%) 0.689
.1 artery 4 of 18 (11%)
Number of surgical procedures
1 5 of 64 (8%)
.1 5 of 32 (16%) 0.189
Type of surgery
at least 1 craniotomy 6 of 58 (10%)
Noncraniotomy 4 of 38 (10%) 0.980
Prescribed dose†
66.6 CGE 3 of 44 (7%)
72 CGE 7 of 52 (13%) 0.304
* One or two internal carotid artery and/or basilar artery.
† Prescribed dose to the tumor.
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uniform dose throughout the right temporal lobe, with the
doses being greatest in its medial portion immediately ad-
jacent to the tumor.
Patient B (#5 of Table 5)
Patient 5, a white 52-year-old woman, developed diplopia
on right lateral gaze and headache in November 1986. A CT
scan showed a sellar mass. The patient had hypopituitarism
since age 20, and had stopped taking her thyroid hormonal
medication at some point prior to presentation. TSH levels
were elevated, and no further investigation was undertaken.
The diplopia resolved, but recurred in October 1987, and
MRI showed a right parasellar and sphenoidal mass. The
tumor had invaded the sphenoid sinus and displaced the
cavernous sinus. Biopsy was obtained, revealing a chor-
doma. Postoperatively, diplopia was intermittent; she was
treated from February through April 1988. The photon
component was given through two opposed lateral fields. A
multiple-field approach, using a noncoplanar isocentric
technique, was used for the proton component of the irra-
diation to deliver the total dose of 66.6 CGE to the primary
target volume (8 cc) in 37 fractions.
In May 1991, the patient experienced the onset of tem-
poral lobe seizures with frequent episodes of panic attacks
and abnormal feelings. An MRI showed the presence of
abnormal T2 enhancing area in the medial aspect of the
right temporal lobe, consistent with temporal lobe damage.
She was started on medications (divalproex [Depakotet]
250 mg q.i.d.), after which she experienced complete con-
trol of the seizures.
Management of TL damage
The development of TL necrosis following irradiation
usually produces moderate to severe symptoms that may be
relieved with corticosteroids and/or anticonvulsants. When
steroids cannot be tapered, undesirable side effects may
occur. An alternative to medical treatment is reoperation
and evacuation of the necrotic area. In these patients, re-
covery after surgery was complete in 1 patient and partial in
a second, who experienced persistent memory loss. A third
patient, on the contrary, remained stable after surgical re-
section with persistent headache; he experienced a local
recurrence and died with progressive local disease.
DISCUSSION
The classical late adverse effect of therapeutic or inci-
dental brain irradiation is localized necrotic reaction, which
occurs typically at a few months to several years after
irradiation and is usually associated with neurological
symptoms that cannot be attributed to recurrent tumor (14).
After high-dose radiation therapy, “the specific endpoint
chosen for complication of the brain is radionecrosis” (2).
Burger et al. (15) provided a clear description of the histo-
logical modifications associated with radiation necrosis in
brains irradiated for gliomas. Coagulation necrosis, vascular
thickening, perivascular fibrosis, calcium and fibrin deposi-
tion, petechiae, and chronic inflammatory cell infiltrates are
combined in varying degrees and must be distinguished
from necrotic changes within the tumor.
The pathogenesis of radionecrosis has not yet been com-
pletely defined. Different hypotheses that have been ad-
vanced are not mutually exclusive. The vascular hypothesis
(16–21) suggests that the major injury is borne by small-
and medium-size vessels and that necrosis is secondary to
ischemia. According to the glial theory (22, 23), irradiation
damages glial cells, particularly the oligodendroglial cells,
leading to white matter cavitation and demyelination. The
immunological hypothesis (24) attributes radiation necrosis
and vascular changes to a response to antigens released
from damaged glial cells.
Radiation necrosis rates, following treatment with mega-
voltage irradiation, are not well defined and there is a need
for more information about the tolerance of healthy tissue to
irradiation, the dose-time relationship (25), and the partial
volumes of healthy tissues receiving variable dose levels
(26). Changes following cranial irradiation have been iden-
tified among survivors of primary CNS tumors and acute
lymphoblastic leukemia, although necrosis following irra-
diation for extracranial tumors has been described (5).
Burger et al. reported 4 cases of radiation necrosis among
17 patients dying with malignant gliomas treated with doses
between 50 and 60 Gy (15). Prevalence of this condition in
autopsied patients does not define the incidence of radione-
crosis among living patients.
Sheline et al. (5) found in the literature 80 cases of brain
necrosis where irradiation was “either the causative agent or
a major contributing factor.” A majority of these patients
Fig. 3. Dose–volume histograms for the temporal lobes of Patient
1 of Table 5. The review of the dose distribution demonstrated a
higher dose in the medial portion of the temporal lobe immediately
adjacent to the tumor.
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had tumors other than gliomas (32 gliomas vs. 48 head and
neck, skin, and pituitary tumors). Twenty patients received
doses of 50 Gy or less with nonconventional fractionation
(2.5 Gy/fraction) and, in 26, the total dose was .70 Gy or
MRE (Megavolt rad equivalent).
Marks et al. (6) reported that 7 (5%) of 139 patients with
brain or pituitary tumors who received .45 Gy in 1.8–2.0
Gy fractionation, developed pathologically demonstrable
cerebral radionecrosis. Necrosis was documented by au-
topsy in 4, at reoperation in 2, and after needle biopsy in 1,
and it was located distant from the tumor in 3, adjacent to
the tumor in 2, and within the tumor bed in 2.
Lee et al. (27) reported on 102 patients with clinical and
CT scan diagnosis of late TL necrosis after radical radiation
therapy for nasopharyngeal carcinoma among 9606 pa-
tients. Although their report is mainly based on the corre-
lation of clinical and CT signs, 11 of the 102 reported
patients had pathology confirmation (3 by biopsy and 9 by
autopsy) of the brain damage; the areas of maximum dam-
age were found in the white matter within the irradiated
volume.
CT scans demonstrate several abnormalities in patients
with CNS radiation necrosis: regions of hypodensity in
white matter, atrophy and areas of frank necrosis (4, 28).
MRI has shown a greater sensitivity to identify these ab-
normalities (29–32) due to alterations in water content that
accompanies such changes and appear bright on T2-
weighted sequences. Constine et al. (29) performed a cor-
relation between neurological symptoms and MRI findings
in patients treated for gliomas. They demonstrated that MRI
was superior to CT in detecting postradiation abnormalities
in the irradiated brain, and in making correlations between
clinical signs and imaging abnormalities. A pattern of in-
creasing severity of MRI changes was established with four
phases documented: Grade I 5 periventricular whitening or
intensity; Grade II 5 focal extension of intense signal into
the white matter; Grade III 5 diffuse extension into white
matter; Grade IV 5 diffuse coalescence of white and grey
matter into intense signal region, loss of architecture, cor-
tical atrophy, and hydrocephalus ex vacuo. The authors
correlated clinical symptoms to MRI grade changes. Seven
patients had Grade III–IV MRI changes; five of these pre-
sented mental impairment and two were asymptomatic.
Such clinical problems developed as long as 7 years after
irradiation, but generally became apparent within 2 years.
Clinical symptoms were correlated to changes in MRI
grade. The incidence of Grade 3 and 4 changes in the white
matter was significantly higher in the patients receiving
whole-brain radiation relative to those receiving local-field
irradiation only (Grade 3 to 4 changes in 50% and 14%,
respectively).
The analysis of the data from the literature allows the
conclusions that (a) Pathology of the brain damage has been
clearly defined; (b) pathologic confirmed cases of brain
necrosis may occur in patients receiving doses in excess of
45 Gy; but (c) it may be difficult to differentiate treatment-
related necrosis from tumor progression in patients with
malignant gliomas, the most frequent disease for which
high-dose brain irradiation is used; and (d) correlation be-
tween neurological and MRI changes may demonstrate a
rate of late effects as high as 12% (29).
The incidence of radionecrosis is probably underesti-
mated in the glioma series because patients die early and the
autopsy rate is low. In pathology series, such as that of
Burger et al. (15), radionecrosis may, on the contrary, be
overestimated because patients may be referred specifically
because of brain damage following radiation therapy, re-
sulting in selection bias.
To our knowledge, no data are available in the literature
about the incidence of white matter necrosis after proton-
based irradiation for intracranial or extracranial tumors.
Urie et al. (33) performed a very detailed analysis of the
normal anatomy, dose distribution, and clinical outcomes of
27 patients treated with protons for skull base tumors, and
found 5 patients with neurological symptoms that were
attributed to radiation injury. They analyzed 594 CNS struc-
tures (22 structures per patient in 27 patients), and found 17
structures with clinically manifest radiation injury and con-
cluded that “for dose fractionation of 1.8–2.0 CGE, the
probability of radiation injury is 5% at 70 CGE (64–81
CGE with 95% confidence).”
Debus et al. (34) analyzed the incidence of brain stem
toxicity in a group of 282 patients treated for chordomas and
chondrosarcomas of the base of the skull treated with com-
bined megavoltage photon and 160-MeV proton radiother-
apy (prescribed doses to the target volume ranging between
63 and 79.2 CGE). They report brain stem symptoms,
attributable to the treatment, in 17 patients (6%), resulting in
death in 3 of them. They suggest that the tolerance of the
brain stem to the fractionated radiotherapy appears to de-
pend on the volume of tissue included in the high-dose
regions, and that an increased risk of brain stem toxicity was
significantly associated with maximum brain stem dose,
volume receiving .50 CGE, .55 CGE, and .60 CGE,
number of surgical procedures, and prevalence of diabetes
mellitus or high blood pressure. Presumably the cause of
death in 3 patients of the 17 reported with brain stem
symptoms may be attributable to brain stem necrosis, but
this is not clearly stated.
Liu et al. (35) tried to determine the incidence of my-
elopathy after high-dose proton and photon radiotherapy to
the cervical spine, for primary or recurrent chordomas and
chondrosarcomas receiving doses ranging between 64.5 and
79.2 CGE. They report that 4 (5.1%) of 78 patients devel-
oped high-grade (RTOG Grade 3 and 4) late toxicity, with
3 patients experiencing sensory deficit, but no motor deficit,
and 1 patient who developed motor deficit with loss of
motor function of one upper extremity. One patient devel-
oped asymptomatic MRI changes and 6 experienced tran-
sient Lhermitt’s syndrome.
In our series of 96 consecutive randomized patients, 10
patients (10.4%) developed clinical symptoms and MRI
changes consistent with radiation necrosis, after high-dose
proton and photon radiation therapy to a portion of the
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brain. Although an underestimation of the true incidence of
necrosis may be possible in this group of patients, the
current series has some features that distinguish it from
other reports in the literature.
Chordomas and chondrosarcomas of the base of the skull
are extradural tumors that, during their local evolution, may
abut or displace the normal brain instead of infiltrating the
white matter as gliomas always do. This separation from the
brain matter usually allows the differentiation of the area of
late brain damage from the tumor site.
Although specific dose–response data for diffuse white
matter changes are unavailable, postradiation necrosis,
which has been described at 45 Gy, is usually not seen
when doses of ,60 Gy are given with conventional
fractionation (5, 36). In our series, all the patients re-
ceived prescribed doses of 66.6 and 72 CGE, at 1.8 CGE
per fraction, 5 treatments per week. However, these doses
were generally conformed to the tumor, and relatively
small volumes of the surrounding healthy brain received
high doses. Indeed, this study shows that necrosis can
occur in patients in whom ,10 cc of healthy brain
parenchyma received higher than 50 CGE, as is shown by
the data reported in Table 7 for the patients with damage
and the Control Group. Nevertheless, as illustrated by the
different theories, the possible pathogenesis of brain ne-
crosis is a complex phenomena that may be induced by
factors other than the direct irradiation of a large area of
white matter to high doses. The inclusion of the network
of microarteries in the high-dose volume, for example,
may produce thickening and occlusion of these blood
vessels followed by ischemia and necrosis.
In addition to the effort to define a possible correlation
between dose and volume to predict TL damage, several
other baseline parameters were considered. Most of these
variables are tumor- or host-related factors that may, in
some way, influence or modify the response to irradiation of
the healthy tissues. Some produce distortion of the normal
anatomy of the brain matter or of the normal blood flow
(e.g., encasing of the large arteries by the tumor), or modify
the environment of the healthy tissues (following more than
one surgical procedure) and were supposed to have some
statistically significant relevance on the occurrence of the
damage. Despite the higher rates of TL damage related to
age, tumor volume, number of surgical procedures prior to
radiation therapy, and prescribed dose to the tumor, only
gender was a significant predictor of damage (p 5 0.0155)
using a univariate (log rank) test. In a stepwise Cox regres-
sion that included gender as a variable, no other baseline
variable significantly improved the predictivity of TL dam-
age. An extended database including more patients and,
consequently, more cases with late side effects might prob-
ably help to demonstrate the predictivity of some of the
variables on TL damage and a prospective study on their
relevance may be necessary.
In conclusion, chordomas and chondrosarcomas of the
base of the skull undergoing high-dose photon and proton
irradiation may represent a good model for estimating
late radiation effects due to their prolonged survival,
without local progression of the tumor, in comparison to
glioma patients. Five-year local recurrence-free survival
has been reported, in fact, to be 95 6 4% and 62 6 9%,
respectively, for chondrosarcomas and chordomas (37).
Current treatment techniques are specifically designed to
reduce total dose and dose per fraction to the temporal
lobe, by treating at least 2 separate portals per day
directed to the tumor, but entering through different
volumes of brain, and by incorporating not only lateral
portals but superior, oblique, or posterior portals into the
overall treatment plan.
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